Profil bibliographique

Aidan G. Gilmartin

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

72Publications signalées

2637Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Microtubule and mitosis dynamicsCancer-related Molecular PathwaysMelanoma and MAPK PathwaysFibroblast Growth Factor ResearchCancer Genomics and Diagnostics

Publications récentes

2026 conference-abstractOpenAlex

Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

Zev A. Wainberg, Jason T. Henry, Haeseong Park, Rasha Cosman et autres

8 citationsJournal of Clinical Oncology

2025 articleOpenAlex

916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors

J. Desai, B. Markman, M. Millward, E. Garralda et autres

11 citationsAnnals of Oncology

2025 articleOpenAlex

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Srđan Verstovšek, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Jay Patel et autres

8 citationsNEJM Evidence

Accès ouvert 2025 articleOpenAlex

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer

Angela Abdollahi, Margaret Favata, Michaël Weber, Valerie Roman et autres

3 citationsPLoS ONE

2025 conference-abstractOpenAlex

Abstract 6071: PD-1xTGFβR2 bispecific Biclonics® antibody INCA33890 augments human T-cell effector functions in vitro and ex vivo

Jun Guan, Aidan G. Gilmartin, Kenji Kimura, Estela Noguera-Ortega et autres

1 citationCancer Research

2024 conference-abstractOpenAlex

MPN-384 A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement

Alessandro M. Vannucchi, Jay Patel, William Shomali, Tracy I. George et autres

3 citationsClinical Lymphoma Myeloma & Leukemia

2024 articleOpenAlex

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement

Alessandro M. Vannucchi, Jay Patel, William Shomali, Tracy I. George et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2024 articleOpenAlex

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement

Alessandro M. Vannucchi, Jay Patel, William Shomali, Tracy I. George et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2024 erratumOpenAlex

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donás et autres

4 citationsNature Medicine

Accès ouvert 2024 articleOpenAlex

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donás et autres

73 citationsNature Medicine

Accès ouvert 2023 articleOpenAlex

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201

Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, Shilpa Gupta et autres

32 citationsAnnals of Oncology

2023 conference-abstractOpenAlex

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Andreas Reiter, Jean‐Jacques Kiladjian, Jay Patel, William Shomali et autres

4 citationsBlood

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.